My Colorectal Cancer has recurred. How does this change my treatment choices, and are new targeted therapies using...

I'll explain how recurrent colorectal cancer treatment options are influenced by biomarker testing, based on current guidelines.

According to the NCCN Guidelines for Colorectal Cancer (2023):

1. Biomarker testing is ESSENTIAL for recurrent disease and should include:

• RAS mutations (KRAS and NRAS)
• BRAF V600E mutation
• MSI (Microsatellite Instability) status
• HER2 amplification (particularly for left-sided tumors)

Treatment options based on biomarkers:

For MSI-High tumors:

• The NCCN and ASCO Guidelines recommend immunotherapy as a preferred option
• FDA-approved options include pembrolizumab or nivolumab (with or without ipilimumab)

For RAS Wild-Type tumors:

• NCCN Guidelines recommend EGFR inhibitors (like cetuximab or panitumumab) in combination with chemotherapy
• Location of tumor (left vs right side) may influence effectiveness

For BRAF V600E Mutated tumors: According to ESMO Guidelines:

• Targeted therapy combinations including BRAF inhibitors (encorafenib) plus cetuximab
• This combination was FDA-approved based on improved survival rates

Additional Considerations: The American Cancer Society emphasizes that treatment for recurrent disease typically involves:

• Combination of different treatment approaches
• Regular monitoring of biomarkers as they may change
• Clinical trial opportunities when available

Important recommendations:

1. Get comprehensive biomarker testing if not already done
2. Discuss results with your oncology team to determine the best treatment sequence
3. Consider clinical trial participation if appropriate

Remember: Treatment choices should be individualized based on:

• Your specific biomarker profile
• Location and extent of recurrence
• Previous treatments received
• Overall health status
• Personal preferences

Always consult with your healthcare team to develop the most appropriate treatment plan for your specific situation.